26 results about "Osteopontin" patented technology

The invention discloses goat milk with hypoglycemic activity and a preparation method thereof, and belongs to the technical field of enzyme engineering. The goat milk is used as a raw material, enzymolysis goat milk with alpha-G inhibitory activity is obtained through compound protease hydrolysis, it is found that the enzymolysis goat milk has hypoglycemic activity, and the goat milk powder with the hypoglycemic activity is further prepared through spray drying. The alpha-G inhibitory peptides in the enzymolysis goat milk are separated and identified, 20 alpha-G inhibitory peptides are found from components with the highest alpha-G inhibition rate, the molecular weight of the alpha-G inhibitory peptides is 377-962 Da, and the alpha-G inhibitory peptides are mainly derived from beta-casein, alpha S1-casein, alpha S2-casein, kappa-casein, beta-lactoglobulin, lactoglobulin and osteopontin of the goat milk. The alpha-G inhibitory peptide is prepared by hydrolyzing the goat milk through the compound enzyme, the amino acid sequence of the alpha-G inhibitory peptide is separated and identified, the goat milk with hypoglycemic activity is developed, and theoretical basis and technical support are provided for subsequent development of hypoglycemic dairy products.

The invention discloses a preparation technology of a lactoferrin and osteopontin compound capable of improving bone health, and belongs to the technical field of food processing. In the compound, the mass ratio of lactoferrin to osteopontin is (3-5): 1, and the pH is 4-5.5. In a zebra fish model, after intervention of the lactoferrin, the osteopontin, the compound or the mixture, compared with a mixture group, the compound group of the lactoferrin and the osteopontin can obviously improve the fluorescence intensity of zebra fish spines, the relative bone mineral density is improved by 31.12%, and compared with a blank group, the relative bone mineral density is improved by 2.39 times. Therefore, the lactoferrin and osteopontin compound with the function of improving bone health can be prepared, and the lactoferrin and osteopontin compound has good application potential.

An antisense oligonucleotide (ASO) that is capable of binding to a target sequence in a mRNA of a secreted phosphoprotein 1 (SPP1) or osteopontin (OPN) gene, the mRNA having a start codon in an open reading frame encoding the SPP1 or OPN, and the target sequence including the start codon in the open reading frame of the mRNA. Binding of the ASO to the target sequence disrupts translation of the ORF encoding the SPP1 or OPN. Alternatively, an ASO wherein the ASO is capable of binding to a target sequence in a pre-mRNA of a SPP1 or OPN gene. Also double-stranded DNA or RNA molecules capable of binding to a target sequence in a mRNA or pre-mRNA of a SPP1 or OPN gene. Additionally, pharmaceutical compositions and methods of treatments using the ASOs or double-stranded DNA or RNA molecules.

Disclosed is a method for diagnosing or predicting a stage of colorectal health status in an individual, including: providing a biological fluid sample of the individual; detecting the content of a marker in the biological fluid sample; and determining the stage of the colorectal health status in the individual according to the detected content of the marker, where the biomarker is selected from: any one or more of trefoil factor 1, trefoil factor 3, insulin-like growth factor binding protein 1, insulin-like growth factor binding protein 4, serine protease inhibitor A1, osteopontin, or growth differentiation factor-15.

Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.

The application provides a composition for promoting bone health and bone formation, and application and products thereof, and belongs to the field of food. The composition of the application is composed of 2'-fucosyllactose, osteopontin and a calcium source, wherein the osteopontin is 1-5 parts, the 2'-fucosyllactose is 1-50 parts and the calcium source is 0.05-50 parts by weight. The composition of the application shows a good synergistic effect in promoting calcium absorption, and can be used for increasing bone density, preventing and treating osteoporosis and the like.

This invention relates to a combination comprising effective amounts of osteopontin and lactoferrin, for use in promoting the socio-emotional development of young individuals. The invention also relates to compositions and methods for promoting the socio-emotional development of young individuals, preferably infants.

This invention relates to the field of food processing technology, and more particularly to a method and application for separating bovine colostrum whey. The method for separating bovine colostrum whey provided by this invention includes: mixing and adjusting bovine colostrum collected at different time points within 72 hours of calving to a raw milk with a total solids content of 14-20%; the raw milk is then defatted and enzymatically hydrolyzed to separate the whey; wherein the defatting temperature is 35-50℃. The method provided by this invention can efficiently separate and prepare bovine colostrum whey, with a whey extraction rate ≥70%. The obtained bovine colostrum whey has a high content of various active proteins. The obtained bovine colostrum whey can be used to prepare functional raw materials such as immunoglobulins, lactoferrin, and osteopontin.

Disclosed herein are methods of treatment for diseases and disorders with modulators of full-length or thrombin-cleaved osteopontin. Particularly disclosed herein are methods comprising treatment of tissue fibrosis (e.g., pulmonary, cardiac, liver, kidney, skin) with antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin.

The invention relates to a method for separating and purifying osteopontin from human milk, which comprises the following steps: (1) pretreatment: collecting human milk and pretreating the human milk to remove fat and cell debris impurities to obtain pretreated emulsion; (2) osteopontin precipitation: adding a precipitator into the pretreated emulsion to precipitate osteopontin, and collecting the precipitate; (3) osteopontin dissolution: adding a solvent capable of dissolving osteopontin into the obtained precipitate, fully mixing, and then removing insoluble substances to obtain an osteopontin crude solution; (4) dialyzing and concentrating: dialyzing and concentrating the osteopontin crude solution to obtain an osteopontin concentrated solution; (5) chromatography: purifying the osteopontin concentrated solution in a chromatography manner to obtain an osteopontin purified solution; and (6) drying: drying the osteopontin purified liquid to obtain osteopontin powder. By adopting the method disclosed by the invention, the osteopontin purity of 95% or more by mass can be efficiently realized.

This invention relates to a nutritional composition comprising osteopontin as an active ingredient, which is used to promote emotional development in young individuals, preferably infants. The invention also relates to uses and methods for promoting emotional development in young individuals, preferably infants.

The invention discloses an application of an expression inhibitor of a muscular blind splicing regulator 1 (MBNL1) in promoting osteogenic differentiation and bone formation of bone marrow mesenchymal stem cells (BMSCs), and particularly discloses an application of the expression inhibitor of the MBNL1 in promoting osteogenic differentiation and bone formation of the BMSCs (bone marrow mesenchymal stem cells). According to the present invention, the in-vitro experiment results prove that the si-MBNL1 transfection on the BMSCs can promote the formation of osteoblast calcium nodules, the activity of the marker enzyme ALP, and the expression of the osteogenic related factor Runt related transcription factor 2 (RUNX2), the ALP, the osteopontin (OPN) and the osteocalcin (OCN), and can improve the osteogenic differentiation ability of the BMSCs, such that the si-MBNL1 transfection on the BMSCs can provide the osteogenic differentiation ability of the BMSCs, and further provide the application of the si-MBNL1 transfection on the BMSCs, and the application of the si-MBNL1 transfection on the BMSCs to the osteogenic differentiation of the BMSCs, according to the invention, an adeno-associated virus 9 (AAV9) carrier is used for constructing an sh-MBNL1 regulation technology as an MBNL1 expression inhibitor, and in-vivo experiments prove that the sh-MBNL1 expression inhibitor can be used for repairing estrogen deficiency type osteoporosis bone loss and promoting fracture healing. According to the invention, a breakthrough direction is provided for clinical early warning of osteoporosis, and a new technical means is provided for clinical osteoporosis or gene therapy for promoting fracture healing.

Methods for characterizing disease activity in patients with systemic lupus erythematosus (SLE). These methods include obtaining blood, serum, plasma, or urine samples from the patient; assessing the expression of biomarkers selected from IFN-α, IL-10, BlyS, IL-7, IFN-γ, TRAIL, IL-15, IP-10 / CXCL10, and IL-4 in the samples; assessing the expression of inflammatory mediators selected from TNFRII, resistin, and osteopontin (OPN) in the samples; assessing SLE-related autoantibody-specific biomarkers selected from dsDNA, chromatin, RiboP, Ro / SSA, La / SSB, Sm, SmRNP, and RNP in the samples; and calculating the Lupus Disease Activity (Immune) Index (LDAII / L-DAI) score. The LDAII / L-DAI score can distinguish between active and low lupus disease activity. Treatment methods are also provided, including administration after determining that the patient has a prognostic risk of transitioning to classified SLE but before reaching the clinical disease classification.

The present application relates to the field of molecular biology and biomedicine technology, and particularly relates to an siRNA with anti-skin cell aging and repair effect and application thereof.The siRNA comprises a guide chain and a passenger chain.The siRNA targets a bone bridge protein coding gene SPP1.The siRNA has excellent anti-aging effect and can be used for preparing anti-aging products.

This invention provides a nutritional composition and its application. The nutritional composition comprises medium- and long-chain fatty acid triglycerides and osteopontin in a mass ratio of 6:1 to 1500:1, which have a synergistic effect in enhancing immunity, particularly in restoring one or more of the number of macrophages, T cells, and neutrophils in an individual.

The present invention generally relates to the dairy industry, and specifically to the isolation and purification of osteopontin and glycomacropeptide, wherein is provided with a process for the isolation of osteopontin (OPN) or glycomacropeptide (GMP) from whey or a whey derived liquid comprising the steps of absorption onto a monolithic chromatography column, an optional washing of the column and subsequent elution of said OPN or GMP using a change in salt concentration and / or pH.

The present invention relates to polymeric membranes and compositions for oral care and various methods of use thereof. In particular, the present invention relates to a composition comprising phosphoprotein and its use in the treatment and prevention of gingival bleeding and in the treatment and prevention of periodontal disease. Preferred compositions comprise osteopontin and derivatives thereof.

This invention relates to a method for separating osteopontin, particularly a method for separating osteopontin from a milk-containing raw material. The method includes: a first separation step, adjusting the milk-containing raw material to a first pH value to cause the osteopontin to co-coagulate with at least one other protein to obtain a first precipitate; a second separation step, mixing the first precipitate with a solution of a first salt to cause at least partial decoagulation of the precipitate to release the osteopontin, and separating to obtain a solution containing osteopontin; a third separation step, adjusting the solution containing osteopontin to a second pH value to obtain a second precipitate containing osteopontin. Optionally, the third separation step is carried out in the presence of a second salt, and the first pH value is such that the osteopontin contained in the first precipitate is at least 70% by mass of the total osteopontin in the milk-containing raw material.

The present application provides a composition for improving intestinal inflammatory symptoms and restoring key flora. Specifically, the present application provides an application of a composition in the preparation of a product for improving intestinal inflammatory symptoms and restoring key flora, wherein the composition comprises 2'-fucosyllactose and osteopontin, and the mass ratio of 2'-fucosyllactose to osteopontin is 1:(0.017-1.3). The present application also provides a food containing the composition, and an application of the composition or the food in the preparation of a product for improving intestinal inflammatory symptoms and restoring key flora.

The present disclosure relates to therapeutic antibodies that target full-length or cleaved osteopontin and methods of use thereof.

The present invention relates to compositions for use in oral care and various methods of their use. In particular, it relates to compositions comprising phosphoproteins and their use in the treatment and prevention of dentine hypersensitivity and the treatment and prevention of xerostomia. Preferred compositions comprise osteopontin and derivatives thereof.

The application provides a cerium-zirconium and arginine nano composite drug targeting an arterial vulnerable plaque microenvironment and preparation and application thereof, including L-arginine, solid cerium-zirconium nanozyme, bone bridge protein short peptide and a liposome carrier. The mass ratio of the L-arginine, the solid cerium-zirconium nanozyme and the bone bridge protein short peptide is 2:5:2, and the mass ratio of the liposome carrier and the total of the three substances is 1:1600-1800. The application innovatively uses a slow-release preparation technology to complete the encapsulation of the cerium-zirconium nanozyme and basic L-arginine, realizes neutralization of a plaque microenvironment, and realizes specific treatment of foam cells through surface modification of bone bridge protein for targeted release of drugs. The compound realizes anti-aging treatment of atherosclerosis, has a small particle size, high biocompatibility, a simple and mature process, low material cost, is stable and reliable, and is a convenient, safe and ideal way for treating AS.

This invention provides a nutritional composition and its application. The nutritional composition comprises medium- and long-chain fatty acid triglycerides and osteopontin in a mass ratio of 6:1 to 2400:1, which have a synergistic effect in promoting myelin development or maintaining myelin health, particularly in promoting the expression of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor.

The invention relates to the technical field of food, and particularly discloses a composition for alleviating hearing loss of middle-aged and elderly people and a product for alleviating hearing loss of middle-aged and elderly people. The composition for alleviating hearing loss of middle-aged and elderly people provided by the invention comprises the following components: polyfructose, osteopontin and alpha-lactalbumin. The components of the composition for alleviating hearing loss of middle-aged and elderly people have a synergistic effect, and age-related hearing loss can be improved through ear-intestine axis bidirectional regulation. Test results show that the composition with a specific ratio for alleviating hearing loss of middle-aged and elderly people provided by the invention can reduce the abundance of enterobacter, improve the abundance of beneficial bacteria bifidobacterium in intestinal tracts, relieve auditory brainstem reflex thresholds under stimulation of different frequencies, inhibit an oxidative stress process and improve the hearing loss of middle-aged and elderly people. The method can be used for preparing middle-aged and elderly hearing loss relieving products.

The present disclosure relates to methods for identifying a subject or treating a subject with fibrosis or fibrosis progression. In some aspects, the method relates to measuring the levels of CD44, CD147 and / or osteopontin (SPP1) relative to a control level in order to guide a therapeutic regimen in a subject with fibrosis or fibrosis progression. The present disclosure also provides anti-Claudin-1 antibodies and fragments thereof and methods of use in diagnosing, providing prognosis or treating fibrosis or fibrosis progression.